kinesin family member 23Genealiases: CDA3 · CDAIII · CDAN3 · CDAN3A · CHO1 · KNSL5
Q-omics provides the consensus-scored KIF23 profile across patient tissues and cancer cell-line models. KIF23 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, KIF23 is differentially expressed in 17, with the highest sampling consensus in BLCA. Additionally, KIF23 protein abundance shows 27,864 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight MESO, BLCA, and LUAD as cancer lineages where KIF23 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KIF23 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KIF23 survival associations across molecular data types. KIF23 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (4) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KIF23 RNA expression–survival associations across cancer types. High KIF23 expression shows unfavorable associations in MESO, KIRP, ACC, KIRC, KICH and LIHC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for KIF23 RNA expression.
This table summarizes KIF23 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 17, while mass-spec protein shows differences in 7. The strongest signals are observed in HNSC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for KIF23. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KIF23 shows higher tumor expression in BLCA, HNSC, LUAD, STAD, COAD and LIHC. The BLCA box plot shows higher KIF23 RNA expression in tumor versus normal tissue (log2 FC = +3.124, t-test p < 0.001).
This table shows molecular features associated with KIF23 in patient tissues and cancer cell lines. In patient samples, KIF23 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, KIF23 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LUNG_NSCLC_LUAD.
